Trinity College Dublin

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers

Retrieved on: 
torsdag, november 9, 2023
Colon, Medication, Weight gain, Research, Argyreia nervosa, CB2, National Center for Advancing Translational Sciences, Senior, Quality of life, Trinity College, Life expectancy, Trinity College Dublin, Cancer, Pain, Patient, Associate, Atrophy, Appetite, Pharmaceutical industry, Medical device, Vitro

The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company’s clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.

Key Points: 
  • The research article, titled “ Cancer-Cachexia-Induced Human Skeletal Muscle Myotube Degeneration is Prevented via Cannabinoid Receptor 2 Agonism in Vitro ,” highlights the promising protective properties of the Company’s clinical asset, ART27.13, in helping prevent muscle degeneration caused by cancer.
  • Senior author Dr. Richard K. Porter, Associate Professor at Trinity College Dublin, Ireland, stated, “This groundbreaking research demonstrated ART27.13’s ability to protect against muscle degeneration associated with colon and lung cancers.
  • The purpose of this new research was to establish whether ART27.13 may additionally impact muscle degradation, a common debilitating effect of cancer and its treatment.
  • Not only did the research show that ART27.13 protects against muscle wasting in the in vitro model, but also shows that the activity was mediated by the CB2 receptor.

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
torsdag, november 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

Retrieved on: 
torsdag, november 9, 2023
University of Los Andes (Colombia), IPO, Biogen, Therapy, Tajikistan State University of Law, Business, & Politics, Tree, Doctor of Philosophy, MBA, Engineering, HEC Paris, Central Executive Committee (PAP), Politics, Growth, Trinity College, Medicine, Paris, Executive Committee, Business, Senior, University of Hamburg, Ethicon, University, Trinity College Dublin, Sanofi, International communication, La Jolla Institute for Immunology, Immunology, Management, Bayer, Merck

BORDEAUX, France, Nov. 9, 2023 /PRNewswire/ -- TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on a disruptive proprietary technology platform, today announced the appointment of three new members to the Executive Team.

Key Points: 
  • "Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships.
  • We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy.
  • Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics.
  • For further information on the Executive Committee, visit www.treefrog.fr

Cohen & Company Capital Markets Continues Strong Momentum, Appoints Gary Quin Senior Advisor, EMEA Investment Banking to Expand Global Reach

Retrieved on: 
måndag, oktober 30, 2023
Credit Suisse, Fairfax Financial, Government, SPAC, Harvard Business School, Capital market, IPO, Sale, Aer Lingus, Vice, Blackstone Inc., Digicel, Investment, Irish government response to the COVID-19 pandemic, Acquisition, University, IA Financial Group, MBA, REIT, Fidelity Investments, Growth, Trinity College, University College Cork, CCM, Pleasure, Commander, U.S. Pacific Fleet, Trinity College Dublin, Senior advisor, NAAC, Financial services, Cryptocurrency, Saudi Aramco

MENLO PARK, Calif. and NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Cohen & Company Capital Markets ("CCM") is pleased to announce the appointment of Gary Quin as Senior Advisor, who will lead CCM's efforts in Europe, the Middle East, and Africa (EMEA).  

Key Points: 
  • Gary brings a wealth of expertise to CCM, including over 25 years of investment banking, operating, and investing experience.
  • Gary previously served as the CEO of North Atlantic Acquisition Corp (NAAC), a Nasdaq-listed SPAC with a primary focus on European acquisition opportunities.
  • Prior to NAAC, he served as Vice Chairman of Credit Suisse's investment banking division in Europe, advising corporations, governments and governmental organizations, financial sponsors and family offices on M&A and capital raising.
  • During his tenure at Credit Suisse, Gary successfully raised $66 billion in both private and public markets.

Risk Strategies Names Margaret Bussiere as Commercial Lines Leader, New York Region

Retrieved on: 
tisdag, oktober 3, 2023
Insurance, Trinity College, DeWitt Stern Group, Risk, Culture, Risk management, History, Bussière, Trinity College Dublin, Acquisition, Commercial property, Fine art, Adviser, Management

BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Risk Strategies , a leading national specialty insurance brokerage and risk management firm, today announced it has appointed Margaret Bussiere as Commercial Lines Leader, New York Region.

Key Points: 
  • BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Risk Strategies , a leading national specialty insurance brokerage and risk management firm, today announced it has appointed Margaret Bussiere as Commercial Lines Leader, New York Region.
  • In this role, Bussiere will be responsible for building and executing the regional strategy for the Commercial Property & Casualty business segment.
  • She joined Risk Strategies through the DeWitt Stern acquisition in 2014 as a Vice President focused on serving the most complex and high valued fine art accounts.
  • “Having been a part of Risk Strategies for almost a decade, I understand our culture and the specialty expertise we have to offer,” said Bussiere.

Philip R. Lane: Disinflation and monetary policy in the euro area

Retrieved on: 
fredag, september 29, 2023
Alliance University (New York City), Personal ordinariate, Insurance, Uncertainty, Trinity College, SMA, European Central Bank, Unemployment, Food, Housing, Depression, Money market, Tourism, Face, Lecture, Enterprise Ireland, Rotation, Overalls, Policy, Communication, Disinflation, Shock, National Institute, Board of directors, Social Research (journal), Frankfurt, Blog, Trinity College Dublin, Nigerian Institute Of Social And Economic Research, Executive Board of the European Central Bank, GDP, ECB, Income, Council, Lifting, 2018 Arkansas Issue 5, Acceleration, International Economics Bulletin, Growth, APP, Remuneration, Environment, Reproduction, Food industry, Management, Cryptocurrency, Agriculture, Renewable energy, Security (finance), Risk management
Key Points: 

Arriello appoints experienced biotech expert, Kate Coleman, as VP of Quality & Compliance

Retrieved on: 
onsdag, september 20, 2023
Trinity College, Industrial microbiology, Microbiology, Senior, Face, Administration, Culture, Bachelor, Fear, Risk management, Quality management, University College Dublin, ATMP, Kate, Research Quality Association, Marketing, Trinity College Dublin, QP, QRM, Quality control, Risk, QA, Master of Science, Quality assurance, Growth, Dublin Institute of Technology, Regulatory affairs, API, Vaccine, Marketing authorisation, Conference, Regulation, QMC, Audit, Pharmaceutical industry, Nursing, EU, Pharmacovigilance, Quality, Sanofi

DUBLIN, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Arriello, a leading provider of integrated Regulatory Affairs, Pharmacovigilance and Auditing & QA solutions and services, has announced that industrial microbiology and quality risk management specialist Kate Coleman, will join the company in September as VP of Quality & Compliance. She joins from PharmaLex, where she was Senior Director/Principal Consultant for Quality Management and Compliance and QMC Head of the UK/Ireland region.

Key Points: 
  • DUBLIN, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Arriello , a leading provider of integrated Regulatory Affairs, Pharmacovigilance and Auditing & QA solutions and services, has announced that industrial microbiology and quality risk management specialist Kate Coleman , will join the company in September as VP of Quality & Compliance.
  • She joins from PharmaLex, where she was Senior Director/Principal Consultant for Quality Management and Compliance and QMC Head of the UK/Ireland region.
  • This last accomplishment, gained in 2009, means Kate can act as a Qualified Person (QP) for clients in the EU.
  • Here she will present on the theme of "QRM and Quality - Making sure fear doesn't undermine your QRM programme" - exploring the purpose of Quality Risk Management.

EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis

Retrieved on: 
fredag, september 15, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Trinity College, Maintenance, Eczema Area and Severity Index, Disease, Civil service commission, AE, Week, Dermatitis, European Medicines Agency, Adherence, Committee for Medicinal Products for Human Use, Quality of life, Atopic dermatitis, Almirall, TCS, Committee, EMA, Trinity College Dublin, BME, Advocate, ALM, Patient, European, Adolescence, United Kingdom, Eli Lilly and Company, Itch, Hospital, AD, EudraCT, Conjunctivitis, EC, Human, Skin, European Commission, Safety, CHMP, Vaccine, Pharmaceutical industry, Dermatology

The positive CHMP opinion is now being reviewed by the European Commission (EC).

Key Points: 
  • The positive CHMP opinion is now being reviewed by the European Commission (EC).
  • “Atopic dermatitis, commonly known as atopic eczema, can have a profound impact on the quality of life for those it affects.
  • "The positive CHMP recommendation for EBGLYSS in moderate to severe AD represents a significant milestone in bringing a next-generation biologic therapy to people living with atopic dermatitis, providing a much needed additional treatment option.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.

Ardagh Group S.A. Announces Paul Coulson to transition from Chairman to Director role

Retrieved on: 
tisdag, september 12, 2023
Trinity College, Yeoman, Ardagh Group, England, Sale, Trinity College Dublin, Salmon, Biodegradable waste, Corporation, United Kingdom, Growth, Stonehage Fleming, Glass, PwC, Management, Bottled water

LUXEMBOURG, Sept. 12, 2023 /PRNewswire/ -- Ardagh Group S.A. ("Ardagh Group"), a leading global supplier of sustainable, infinitely recyclable metal and glass packaging today announces a decision by Paul Coulson to step down as Chairman of Ardagh Group and of its 76%-owned subsidiary Ardagh Metal Packaging S.A. ("Ardagh Metal Packaging"), on November 15, 2023.

Key Points: 
  • LUXEMBOURG, Sept. 12, 2023 /PRNewswire/ -- Ardagh Group S.A. ("Ardagh Group"), a leading global supplier of sustainable, infinitely recyclable metal and glass packaging today announces a decision by Paul Coulson to step down as Chairman of Ardagh Group and of its 76%-owned subsidiary Ardagh Metal Packaging S.A. ("Ardagh Metal Packaging"), on November 15, 2023.
  • Mr Coulson will be succeeded by Herman Troskie who currently serves as a director of Ardagh Group, Ardagh Metal Packaging and ARD Holdings S.A. ("ARD Holdings"), the ultimate parent of Ardagh Group.
  • Mr Coulson will remain a Director of Ardagh Group, Ardagh Metal Packaging and ARD Holdings, and will remain the controlling shareholder of ARD Holdings.
  • Herman Troskie (53), a director of Ardagh Group, Ardagh Metal Packaging and ARD Holdings, will succeed Paul Coulson as Chairman of all three companies and will join Ardagh on a full-time basis in November.

ALS Finding a Cure, The ALS Association Partner to Reduce Time to Initial ALS Diagnosis

Retrieved on: 
torsdag, augusti 17, 2023
Massachusetts General Hospital, Trinity College, Neuron, Partnership, Drug development, Speech, Electroencephalography, Spinal cord, C9orf72, Quality of life, RNA, Research, Brain, Cell, Biomarker, Cytoplasm, Messenger, ALS Association, Brain cell, Harvard Medical School, Trinity College Dublin, The, Protein, Johns Hopkins University, Patient, Mass, Risk, EEG, Blood, Cancer, Medicine, Neurology, CSF, Diagnosis, Hospital, Early, ALS, Gene, Peptide, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Management

BOSTON and BOYNTON BEACH, Fla., Aug. 17, 2023 /PRNewswire/ -- ALS Finding a Cure® (ALSFAC) and The ALS Association announced today seven new grants worth a total of $2 million to support the development of early diagnostics for ALS.

Key Points: 
  • To receive an ALS diagnosis, patients must first undergo a battery of tests designed to rule out other conditions.
  • This is highly problematic because it can take a year – or sometimes even longer – for a person with ALS to receive the correct diagnosis.
  • To address this challenge, ALSFAC launched the Early ALS Diagnostics Initiative to identify promising molecular, digital, imaging, and electrophysiological diagnostic approaches for ALS.
  • After receiving a Partnership Grant from The ALS Association, ALSFAC was able to increase the number of projects supported by the initiative and expand its reach internationally.